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INTRODUCTION
Epilepsy is associated with a high prevalence of reproductive dysfunction in men (1) and women (2, 3) . These disorders include subfertility, anovulation, menstrual disturbance, hyperandrogenism, lowered effectiveness of oral contraception, adverse pregnancy outcomes in women (2, 3) and sexual dysfunction, androgen deficiency symptoms, testicular atrophy, impaired spermatogenesis and subfertility in men (1) compared with age-matched non-epileptics. These effects appear to be multifactorial with reproductive endocrine effects due to anti-convulsant drugs and epilepsy itself as well as psychosocial factors all contributing to the high prevalence of reproductive disorders.
Among anticonvulsants, carbamazepine (CBZ) and valproate (VPA) are among the two most widely used. In epileptic patients, increased blood steroid hormone binding globulin (SHBG) concentrations are the most consistent change observed in reproductive endocrine parameters with anticonvulsant drugs (4, 5) . Increased SHBG reduces metabolic clearance of testosterone (6) and could thereby impair endogenous sex steroid action. It is unlikely, however, this is sufficient to explain the diversity of reproductive disorders of patients on long-term anticonvulsants (1-3) and other pathogenic mechanisms are likely to be involved.
The possibility that CBZ and VPA may have reproductive endocrine effects due to interaction of these drugs with the sex hormone receptors, androgen receptor (AR), estrogen receptor (ER) and progesterone receptor (PR) has not been evaluated. All three receptors belong to a large superfamily of nuclear hormone receptors that share a well-conserved DNA-binding domain (DBD), a structurally conserved ligand-binding domain (LBD) and an N-terminal domain with no homology between the different receptors (7). After ligand binding, the receptor dimerizes and binds to hormone response elements located within the promoters of hormone-responsive genes to act as a ligand-activated transcription factor. Drugs can interfere with this receptormediated process by many potential mechanisms including altering blood hormone levels (via changes in synthesis, distribution, metabolism or clearance), modifying steroid receptor expression levels, directly binding to the receptor to mimic or block steroid function or interacting with post-receptor co-regulator proteins. So far only the first possibility has been considered in any detail. We therefore utilised a system whereby each of the mammalian sex steroid receptors are stably introduced into the yeast strain Saccharomyces cerevisae to function as steroid-dependent transcription activators. This yeast reporter assays can then serve as useful tools for studying mammalian steroid receptor function. In the present study, therefore we used yeastbased AR, PR or ER in-vitro bioassays to investigate potential interactions of CBZ or VPA with these sex steroid hormone receptors. We show that VPA, but not CBZ, antagonizes both AR and PR action without effects on ER.
MATERIALS AND METHODS

Materials
Hormones, valproate and carbamazapine were obtained from Sigma-Aldrich (Castle Hill, NSW, Australia) and dissolved in ethanol for stock concentrations.
Plasmids and Reporter Gene Constructs
The full-length hPR cDNA plasmid and the PRE-ß-galactosidase reporter plasmid were kindly provided by Professor DP McDonnell. Yeast strain YPH500 (MATa, ura3- 
Yeast culture
Yeast transformants were grown overnight at 30C with vigorous orbital shaking at 300 rpm in CSM-leu-ura (ER,AR BIO101) or CSM-trp-ura (PR, BIO101). Following overnight culture, the yeast culture was subcultured in fresh medium and allowed to grow until early-mid-log phase (OD600nm ~1.0).
Estrogen, progesterone and androgen receptor assays
For AR and ER bioassays, yeast from early-mid-log phase growth were diluted (to OD600=1.0) in selective medium (CSM-leu-ura) plus 100 M CuSO 4 to induce receptor production. For the PR bioassay, yeast were diluted (to OD600=0.7) in selective medium (CSM-trp-ura). Diluted yeast were aliquoted into 24-well culture plates (500 l/well) and 5 l doses of steroid or drug were added. galactosidase. Dose-responses were fitted to a 4 parameter sigmoid curve using nonlinear regression option in Sigmaplot version 8.
ß-galactosidase assay
After incubation, the yeast culture samples were transferred to 1.7 ml microcentrifuge tubes, centrifuged at 3,000 rpm, and the cells resuspended in 250 l of assay buffer (60 mM Na 2 HPO 4 , 40 mM NaH 2 PO 4 , 10 mM KCl, 1 mM MgSO 4 ,). Cells were incubated on ice for 15 mins and then lysed by vortexing in the presence of 4.5 l 0.1% SDS and 9 l chloroform. Lysate was then warmed to 30C (5 mins) before 30
l ONPG (4mg/ml) added and incubated at 30C until formation of yellow color.
Reaction was stopped with addition of 75 l sodium carbonate (1M 
Statistical analysis
Results of the experimental studies are reported as mean+SE compared to controls.
Unpaired Student's t-tests were used to determine the significance of changes between groups. A value of P<0.05 was regarded as significant.
RESULTS
The dose-response characteristics of the yeast PR, AR and ER bioassays were established by measuring the response to the receptor's cognate ligands progesterone, testosterone and estradiol, respectively, over the steroid concentration range from 10 -6 M to 10 -16 M (Figure 1 ).
The potential agonist activity of carbamazepine and valproate were evaluated at 10 M concentration. Neither drug produced nonspecific yeast cell toxicity at this dose.
Neither carbamazepine nor valproate displayed agonist activity for any of the 3 steroid hormone receptors (Figure 2 ).
The antagonist activity of carbamazepine and valproate were evaluated at 10 M Valproate is among the most frequently prescribed anticonvulsant drugs used by more than 2 million people daily (16) . Its role in the reproductive endocrine disturbances frequently present in men and women with epilepsy is controversial (1, 11, 13, 16) . As well as a broad spectrum of antiepileptic drug, valproate is also prescribed as a mood stabiliser for bipolar disorders, for neuropathic pain including headache and for migraine prophylaxis (17, 18 ). The present study shows that VPA, at concentrations much lower than therapeutic blood levels, blocks AR and PR, but not ER, action in an in-vitro bioassay. By contrast, carbamazepine had no detectable agonist or antagonist steroidal bioactivity and neither VPA nor CBZ had any sex steroid agonist activity in vitro. These findings indicate that valproate may produce clinical effects as an antiandrogen and anti-progestin when used as an anticonvulsant.
The low fertility of women with epilepsy (9, 10, 19) has many contributing factors including social as well as biological factors. The strong PR antagonism by valproate, detectable at 10 M and nearly complete at 100 M compared with blood therapeutic concentrations of 350-700 M, suggests some biological effects in women may be at least partly due to impaired PR-mediated progesterone action on reproductive tissues notably the uterus, breast and ovary. The anti-progestin effects of valproate may be a previously unrecognised factor contributing to the low fertility of women with epilepsy, notably to their otherwise unexplained higher rates of apparent miscarriage (8) . In addition, anti-progestin effects may contribute to the higher frequency of anovulation among valproate-treated women with epilepsy (20) as mice null for PRA, but not PRB, fail to ovulate (21, 22) . Further studies are required to clarify the contribution and and a range of metabolic effects notably increasing blood leptin and insulin, but decreasing IGFBP1, levels (11, 32, 38, 39) .
Whether the anti-androgenic effects of valproate have any clinical significance in women, where blood androgens are normally at levels equivalent to castrate men or children remains doubtful. At the level of the ovarian follicle these effects may stimulate ovarian androgen synthesis (38) as well as inhibiting follicular aromatization (40, 41) . In normal non-epileptic rats, long-term VPA treatment induced endocrine changes and increased the number of ovarian follicular cysts (42) . Similarly, in male rats high doses of valproate retards fertility, inhibit fertility, testicular weight and spermatogenesis as well as epididymal and prostate weight in rodents and larger mammals (43) (44) (45) (46) (47) (48) . While these changes are likely to be due to the lowered blood testosterone concentrations, valproate does not directly inhibit androgen biosynthesis (49, 50) . The findings of increased LH and FSH in some (42) but not all (46) studies is consistent with valproate's anti-androgen action in an in-vitro bioassay.
In conclusion, we have shown using a yeast-based in-vitro bioassay for steroid hormones that VPA, a commonly used anticonvulsant for treatment of epilepsy and bipolar disorder, is an antiandrogen and antiprogestin but has no antiestrogen effects.
These effects of VPA are evident at concentrations well below therapeutic blood concentrations of valproate when used to treat epilepsy or bipolar mood disorder. By contrast, carbemazapine had no sex steroid hormone receptor bioactivity. These findings suggest a new reproductive endocrine mechanism for valproate in the frequent reproductive dysfunction reported in valproate treated patients.
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